264 related articles for article (PubMed ID: 33092487)
1. Anti-virulence strategies for
Stewart D; Anwar F; Vedantam G
Gut Microbes; 2020 Nov; 12(1):1802865. PubMed ID: 33092487
[No Abstract] [Full Text] [Related]
2. Advances in the diagnosis and treatment of Clostridium difficile infections.
Peng Z; Ling L; Stratton CW; Li C; Polage CR; Wu B; Tang YW
Emerg Microbes Infect; 2018 Feb; 7(1):15. PubMed ID: 29434201
[TBL] [Abstract][Full Text] [Related]
3. Ridinilazole: a novel therapy for Clostridium difficile infection.
Vickers RJ; Tillotson G; Goldstein EJ; Citron DM; Garey KW; Wilcox MH
Int J Antimicrob Agents; 2016 Aug; 48(2):137-43. PubMed ID: 27283730
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
[TBL] [Abstract][Full Text] [Related]
5. Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
Hawes AM; Desai A; Patel PK
Anaerobe; 2021 Aug; 70():102384. PubMed ID: 34029702
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial Activity of Tannic Acid
Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
[TBL] [Abstract][Full Text] [Related]
7. Pathogenicity and virulence of
Buddle JE; Fagan RP
Virulence; 2023 Dec; 14(1):2150452. PubMed ID: 36419222
[No Abstract] [Full Text] [Related]
8. Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study.
Wen X; Shen C; Xia J; Zhong LL; Wu Z; Ahmed MAEE; Long N; Ma F; Zhang G; Wu W; Luo J; Xia Y; Dai M; Zhang L; Liao K; Feng S; Chen C; Chen Y; Luo W; Tian GB
Microbiol Spectr; 2022 Feb; 10(1):e0132221. PubMed ID: 35019676
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
11. The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients.
Krutova M; Capek V; Nycova E; Vojackova S; Balejova M; Geigerova L; Tejkalova R; Havlinova L; Vagnerova I; Cermak P; Ryskova L; Jezek P; Zamazalova D; Vesela D; Kucharova A; Nemcova D; Curdova M; Nyc O; Drevinek P
Antimicrob Resist Infect Control; 2020 Jun; 9(1):98. PubMed ID: 32605598
[TBL] [Abstract][Full Text] [Related]
12. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial resistance in Clostridioides difficile.
O'Grady K; Knight DR; Riley TV
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2459-2478. PubMed ID: 34427801
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response.
Vedantam G; Clark A; Chu M; McQuade R; Mallozzi M; Viswanathan VK
Gut Microbes; 2012; 3(2):121-34. PubMed ID: 22555464
[TBL] [Abstract][Full Text] [Related]
15. Clostridioides difficile Biofilm.
Vuotto C; Donelli G; Buckley A; Chilton C
Adv Exp Med Biol; 2024; 1435():249-272. PubMed ID: 38175479
[TBL] [Abstract][Full Text] [Related]
16. Clostridioides difficile infection evaluation and management in the emergency department.
Carius BM; Liang SY; Koyfman A; Long B
Am J Emerg Med; 2020 Oct; 38(10):2203-2208. PubMed ID: 33071079
[TBL] [Abstract][Full Text] [Related]
17. Clostridioides difficile infection in Africa: A narrative review.
Kullin B; Abratt VR; Reid SJ; Riley TV
Anaerobe; 2022 Apr; 74():102549. PubMed ID: 35337974
[TBL] [Abstract][Full Text] [Related]
18. Microbiota-based markers predictive of development of Clostridioides difficile infection.
Berkell M; Mysara M; Xavier BB; van Werkhoven CH; Monsieurs P; Lammens C; Ducher A; Vehreschild MJGT; Goossens H; de Gunzburg J; Bonten MJM; Malhotra-Kumar S;
Nat Commun; 2021 Apr; 12(1):2241. PubMed ID: 33854066
[TBL] [Abstract][Full Text] [Related]
19. Progress on mechanisms of antibiotic resistance in Clostridioides difficile.
Xu T; Huang HH
Yi Chuan; 2023 Nov; 45(11):1028-1038. PubMed ID: 38764268
[TBL] [Abstract][Full Text] [Related]
20. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
